BPG is committed to discovery and dissemination of knowledge
Case Report
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 114021
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.114021
Clinicopathologic features of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma: A case report and review of literature
Wan-Qi Yao, Xin-Yi Ma, Gui-Hua Wang
Wan-Qi Yao, Gui-Hua Wang, Department of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 311112, Zhejiang Province, China
Xin-Yi Ma, Department of Pathology, Pathological Diagnosis Center of Dian Diagnostic Technology Group Co., Hangzhou 311112, Zhejiang Province, China
Author contributions: Yao WQ obtained all the required data and drafted the article after literature review; Ma XY responsible for performing immunohistochemical staining; Wang GH critically revised the article and approved the final version of the article.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this article and any accompanying data.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Gui-Hua Wang, MD, Professor, Department of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, No. 1260 Kangliang Street, Liangzhu Street, Hangzhou 311112, Zhejiang Province, China. mamaninghao@163.com
Received: September 11, 2025
Revised: November 2, 2025
Accepted: December 1, 2025
Published online: January 15, 2026
Processing time: 124 Days and 0.9 Hours
Abstract
BACKGROUND

SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma is a highly aggressive tumor, and spontaneous splenic rupture (SSR) as its presenting manifestation is rarely reported among pancreatic malignancies.

CASE SUMMARY

We herein report a rare case of a 59-year-old female who presented with acute left upper quadrant abdominal pain without any history of trauma. Abdominal imaging demonstrated a heterogeneous splenic lesion with hemoperitoneum, raising clinical suspicion of SSR. Emergency laparotomy revealed a pancreatic tumor invading the spleen and left kidney, with associated splenic rupture and dense adhesions, necessitating en bloc resection of the distal pancreas, spleen, and left kidney. Histopathology revealed a biphasic malignancy composed of moderately differentiated pancreatic ductal adenocarcinoma and an undifferentiated carcinoma with rhabdoid morphology and loss of SMARCB1 expression. Immunohistochemical analysis confirmed complete loss of SMARCB1/INI1 in the undifferentiated component, along with a high Ki-67 index (approximately 80%) and CD10 positivity. The ductal adenocarcinoma component retained SMARCB1/INI1 expression and was positive for CK7 and CK-pan. Transitional zones between the two tumor components suggested progressive dedifferentiation and underlying genomic instability. The patient received adjuvant chemotherapy with gemcitabine and nab-paclitaxel and maintained a satisfactory quality of life at the 6-month follow-up.

CONCLUSION

This study reports a rare case of SMARCB1/INI1-deficient undifferentiated rhabdoid carcinoma of the pancreas combined with ductal adenocarcinoma, presenting as SSR - an exceptionally uncommon initial manifestation of pancreatic malignancy.

Keywords: Pancreatic undifferentiated carcinoma; SMARCB1/INI1; Spontaneous splenic rupture; Rhabdoid features; Switch/sucrose non-fermentable; Chemotherapy; Case report

Core Tip: SMARCB1-deficient undifferentiated rhabdoid carcinoma of the pancreas represents a highly aggressive and rare neoplasm. This study suggests that aggressive multimodal therapy, including surgical resection and chemotherapy, may prolong survival in selected patients; however, the overall prognosis remains poor. Given its distinct molecular characteristics and potential resistance to standard therapies, further research into targeted treatment approaches and prospective clinical studies is urgently warranted.

Write to the Help Desk